Importer of Controlled Substances Application: Cerilliant Corporation, 43404-43407 [2017-19067]
Download as PDF
<![CDATA[
43404
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1071]
Certain Wireless Audio Systems and
Components Thereof Institution of
Investigation
U.S. International Trade
Commission
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
August 10, 2017, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Broadcom Limited of San Jose,
California and Avago Technologies
General IP (Singapore) Pte. Ltd. of
Singapore. An amended complaint was
filed on August 16, 2017, and
supplements to the amended complaint
were filed on August 30, 2017. The
amended complaint, as supplemented,
alleges violations of section 337 based
upon the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain wireless audio
systems and components thereof by
reason of infringement of U.S. Patent
No. 6,684,060 (‘‘the ’060 patent’’). The
amended complaint further alleges that
an industry in the United States exists
as required by the applicable Federal
Statute.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The amended complaint, as
supplemented, except for any
confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW., Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:16 Sep 14, 2017
Jkt 241001
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2017).
Scope of Investigation: Having
considered the amended complaint, the
U.S. International Trade Commission,
on September 8, 2017, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain wireless audio
systems and components thereof by
reason of infringement of claim 20 of the
’060 patent; and whether an industry in
the United States exists as required by
subsection (a)(2) of section 337;
(2) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are:
Broadcom Limited, 1320 Ridder Park
Drive, San Jose, CA 95131
Avago Technologies General IP
(Singapore) Pte. Ltd., 1 Yinshun
Avenue 7, Singapore, 768923
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the amended complaint is to be
served:
DTS, Inc., 5220 Las Virgenes Road,
Calabasas, CA 91302
Phorus, Inc., 5220 Las Virgenes Road,
Calabasas, CA 91302
MartinLogan, Ltd., 2101 Delaware
Street, Lawrence, KS 66046–3149
Paradigm Electronics Inc., 205 Annagem
Boulevard, Mississauga, ON L5T 2V1,
Canada
Anthem Electronics, Inc., 205 Annagem
Boulevard, Mississauga, ON L5T 2V1,
Canada
Wren Sound Systems, LLC, 169
Gateshead Way, Phoenixville, PA
19460
McIntosh Laboratory, Inc., 2 Chambers
Street, Binghamton, NY 13903–2699
Definitive Technology, 11433 Cronridge
Drive, Suite K, Owings Mills, MD
21117
Polk Audio Inc., 1 Viper Way, Vista, CA
92081
(c) The Office of Unfair Import
Investigations, U.S. International Trade
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
Commission, 500 E Street SW., Suite
401, Washington, DC 20436; and
(3) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the amended complaint
and the notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the amended complaint
and the notice of investigation.
Extensions of time for submitting
responses to the amended complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
amended complaint and in this notice
may be deemed to constitute a waiver of
the right to appear and contest the
allegations of the amended complaint
and this notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the amended complaint and
this notice and to enter an initial
determination and a final determination
containing such findings, and may
result in the issuance of an exclusion
order or a cease and desist order or both
directed against the respondent.
By order of the Commission.
Issued: September 11, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–19597 Filed 9–14–17; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cerilliant Corporation
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 16, 2017. Such
persons may also file a written request
DATES:
E:\FR\FM\15SEN1.SGM
15SEN1
43405
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
for a hearing on the application on or
before October 16, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on July 13,
2017, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock,
Texas 78665 applied to be registered as
an importer of the following basic
classes of controlled substances:
mstockstill on DSK30JT082PROD with NOTICES
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3–FMC) .............................................................................................................................
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
4-Fluoro-N-methylcathinone (4–FMC) .............................................................................................................................
Pentedrone (a-methylaminovalerophenone) ...................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
4-Methyl-N-ethylcathinone (4–MEC) ...............................................................................................................................
Naphyrone .......................................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................
Fenethylline .....................................................................................................................................................................
Methaqualone ..................................................................................................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ..................................................................................................
SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................
5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .................
AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ......................................................................................................................
AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .........................................
THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ...................................................................
AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide .................
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide ..............................................................
JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ..................................................................................................
SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ....................................................................
JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ..............................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) .....................................................................................................
UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................
JWH–073 (1-Butyl-3-(1-naphthoyl)indole) .......................................................................................................................
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ..........................................................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) .......................................................................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ......................................................................................................
PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .................................................................................................
5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................
Alpha-ethyltryptamine ......................................................................................................................................................
Ibogaine ...........................................................................................................................................................................
CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................
CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ..........................................
Lysergic acid diethylamide ..............................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ..............................................................................................
Marihuana ........................................................................................................................................................................
Parahexyl .........................................................................................................................................................................
Mescaline .........................................................................................................................................................................
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C–T–2 ) ..........................................................................................
3,4,5-Trimethoxyamphetamine ........................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine .............................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine ..........................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine .............................................................................................................................
2,5-Dimethoxyamphetamine ............................................................................................................................................
JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ......................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
5-Methoxy-3,4-methylenedioxyamphetamine ..................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ..................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine .......................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
VerDate Sep<11>2014
17:07 Sep 14, 2017
Jkt 241001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
E:\FR\FM\15SEN1.SGM
15SEN1
1233
1235
1237
1238
1246
1248
1249
1258
1475
1480
1503
2565
6250
7008
7011
7012
7019
7023
7024
7031
7035
7048
7081
7104
7118
7122
7144
7173
7200
7201
7203
7222
7225
7249
7260
7297
7298
7315
7348
7360
7374
7381
7385
7390
7391
7392
7395
7396
7398
7400
7401
7402
7404
7405
7411
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
43406
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
mstockstill on DSK30JT082PROD with NOTICES
Controlled substance
Drug code
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Alpha-methyltryptamine ...................................................................................................................................................
Bufotenine ........................................................................................................................................................................
Diethyltryptamine .............................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
Psilocybin .........................................................................................................................................................................
Psilocyn ...........................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ....................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ....................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...............................................................................................................................
N-Benzylpiperazine ..........................................................................................................................................................
4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) .....................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) ..................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C–E ) ....................................................................................................
2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) .................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) .......................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C–C) ..................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C–N) ....................................................................................................
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C–P) .............................................................................................
2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C–T–4 ) ..................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B–NBOMe) ....................................................
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C–NBOMe) ....................................................
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I–NBOMe) .........................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Butylone ...........................................................................................................................................................................
Pentylone .........................................................................................................................................................................
alpha-pyrrolidinopentiophenone (a-PVP) ........................................................................................................................
alpha-pyrrolidinobutiophenone (a-PBP) ..........................................................................................................................
AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ...................................................................................................
Desomorphine .................................................................................................................................................................
Etorphine (except HCl) ....................................................................................................................................................
Codeine methylbromide ...................................................................................................................................................
Heroin ..............................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Normorphine ....................................................................................................................................................................
Pholcodine .......................................................................................................................................................................
U–47700 (3,4-dichloro-N-[2-dimethylamino)cyclohexy]-N-methylbenzamide) ................................................................
AH–7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) ..................................................................
Acetylmethadol ................................................................................................................................................................
Allylprodine ......................................................................................................................................................................
Alphacetylmethadol except levo-alphacetylmethadol ......................................................................................................
Alphameprodine ...............................................................................................................................................................
Alphamethadol .................................................................................................................................................................
Betacetylmethadol ...........................................................................................................................................................
Betameprodine ................................................................................................................................................................
Betamethadol ...................................................................................................................................................................
Betaprodine .....................................................................................................................................................................
Dextromoramide ..............................................................................................................................................................
Dipipanone .......................................................................................................................................................................
Hydroxypethidine .............................................................................................................................................................
Noracymethadol ...............................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Normethadone .................................................................................................................................................................
Racemoramide ................................................................................................................................................................
Trimeperidine ...................................................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................................
Tilidine .............................................................................................................................................................................
Para-Fluorofentanyl .........................................................................................................................................................
3-Methylfentanyl ..............................................................................................................................................................
Alpha-methylfentanyl .......................................................................................................................................................
Acetyl-alpha-methylfentanyl .............................................................................................................................................
Beta-hydroxyfentanyl .......................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ........................................................................................................................................
Alpha-methylthiofentanyl .................................................................................................................................................
3-Methylthiofentanyl .........................................................................................................................................................
Thiofentanyl .....................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
VerDate Sep<11>2014
17:07 Sep 14, 2017
Jkt 241001
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
E:\FR\FM\15SEN1.SGM
15SEN1
7431
7432
7433
7434
7435
7437
7438
7439
7455
7458
7470
7493
7498
7508
7509
7517
7518
7519
7521
7524
7532
7535
7536
7537
7538
7540
7541
7542
7545
7546
7694
9055
9056
9070
9200
9307
9313
9314
9547
9551
9601
9602
9603
9604
9605
9607
9608
9609
9611
9613
9622
9627
9633
9634
9635
9645
9646
9661
9750
9812
9813
9814
9815
9830
9831
9832
9833
9835
1105
1724
2125
2270
2315
2550
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
43407
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
Controlled substance
Drug code
Nabilone ...........................................................................................................................................................................
1-Phenylcyclohexylamine ................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Racemethorphan .............................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards and
distribution to their research and
forensic customers.
In reference to drug code 7360 the
company plans to import a synthetic
cannabidiol. No other activity for this
drug code is authorized for this
registration.
Placement of these drug codes onto
the company’s registration does not
translate into automatic approval of
subsequent permit applications to
import controlled substances. Approval
of permit applications will occur only
when the registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approval or non-approved finished
dosage forms for commercial sale.
Dated: August 31, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–19067 Filed 9–14–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
National Institute of Justice
mstockstill on DSK30JT082PROD with NOTICES
[OMB Number 1121–NEW]
Agency Information Collection
Activities: Proposed New Information
Collection Activity; Comment Request,
Proposed Study Entitled ‘‘Evaluation of
the Bureau of Justice Assistance
Sexual Assault Kit Initiative’’
National Institute of Justice,
U.S. Department of Justice.
AGENCY:
VerDate Sep<11>2014
17:07 Sep 14, 2017
Jkt 241001
ACTION:
30-Day notice.
The Department of Justice
(DOJ), Office of Justice Programs,
National Institute of Justice, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
November 14, 2017.
FOR FURTHER INFORMATION CONTACT:
Written comments and/or suggestions
regarding the items contained in this
notice, especially the estimated public
burden and associated response time,
should be directed to Christine
Crossland, National Institute of Justice,
Office of Research & Evaluation, 810
Seventh Street NW., Washington, DC
20531 (overnight 20001) or via email at
christine.crossland@ojp.usdoj.gov.
Written comments and/or suggestions
can also be sent to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503 or sent
to OIRA_submissions@omb.eop.gov.
SUPPLEMENTARY INFORMATION: This
process is conducted in accordance with
5 CFR 1320.10. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the National Institute of
SUMMARY:
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
7379
7460
7471
8501
8603
9010
9120
9180
9190
9210
9220
9230
9273
9648
9668
9732
9737
9739
9740
9743
9780
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Justice, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether, and if so how, the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection: Site
visits, which will include individual
and group interviews.
2. The Title of the Form/Collection:
Evaluation of the Bureau of Justice
Assistance Sexual Assault Kit Initiative.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The applicable component within the
U.S. Department of Justice is the
National Institute of Justice in the Office
of Justice Programs.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract: Sexual assault kits (SAKs) are
invaluable tools used in investigations
to collect evidence such as DNA and to
document injuries from alleged victims;
this evidence in turn is used to identify
and prosecute offenders and to
exonerate innocent suspects. Despite the
importance of SAKs, backlogs of
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Pages 43404-43407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19067]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Cerilliant
Corporation
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before October 16, 2017.
Such persons may also file a written request
[[Page 43405]]
for a hearing on the application on or before October 16, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on July
13, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round
Rock, Texas 78665 applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
3-Fluoro-N-methylcathinone (3-FMC). 1233 I
Cathinone.......................... 1235 I
Methcathinone...................... 1237 I
4-Fluoro-N-methylcathinone (4-FMC). 1238 I
Pentedrone ([alpha]- 1246 I
methylaminovalerophenone).
Mephedrone (4-Methyl-N- 1248 I
methylcathinone).
4-Methyl-N-ethylcathinone (4-MEC).. 1249 I
Naphyrone.......................... 1258 I
N-Ethylamphetamine................. 1475 I
N,N-Dimethylamphetamine............ 1480 I
Fenethylline....................... 1503 I
Methaqualone....................... 2565 I
JWH-250 (1-Pentyl-3-(2- 6250 I
methoxyphenylacetyl) indole).
SR-18 (Also known as RCS-8) (1- 7008 I
Cyclohexylethyl-3-(2-
methoxyphenylacetyl) indole).
5-Flouro-UR-144 and XLR11 [1-(5- 7011 I
Fluoro-pentyl)1H-indol-3-
yl](2,2,3,3-
tetramethylcyclopropyl)methanone.
AB-FUBINACA (N-(1-amino-3-methyl-1- 7012 I
oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide).
JWH-019 (1-Hexyl-3-(1- 7019 I
naphthoyl)indole).
AB-PINACA (N-(1-amino-3-methyl-1- 7023 I
oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide).
THJ-2201 [1-(5-fluoropentyl)-1H- 7024 I
indazol-3-yl](naphthalen-1-
yl)methanone.
AB-CHMINACA (N-(1-amino-3-methyl-1- 7031 I
oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-
carboxamide.
ADB-PINACA (N-(1-amino-3,3-dimethyl- 7035 I
1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide).
APINACA and AKB48 N-(1-Adamantyl)-1- 7048 I
pentyl-1H-indazole-3-carboxamide.
JWH-081 (1-Pentyl-3-(1-(4- 7081 I
methoxynaphthoyl) indole).
SR-19 (Also known as RCS-4) (1- 7104 I
Pentyl-3-[(4-methoxy)-benzoyl]
indole.
JWH-018 (also known as AM678) (1- 7118 I
Pentyl-3-(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1- 7122 I
naphthoyl) indole).
UR-144 (1-Pentyl-1H-indol-3- 7144 I
yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
JWH-073 (1-Butyl-3-(1- 7173 I
naphthoyl)indole).
JWH-200 (1-[2-(4-Morpholinyl)ethyl]- 7200 I
3-(1-naphthoyl)indole).
AM2201 (1-(5-Fluoropentyl)-3-(1- 7201 I
naphthoyl) indole).
JWH-203 (1-Pentyl-3-(2- 7203 I
chlorophenylacetyl) indole).
PB-22 (Quinolin-8-yl 1-pentyl-1H- 7222 I
indole-3-carboxylate).
5F-PB-22 (Quinolin-8-yl 1-(5- 7225 I
fluoropentyl)-1H-indole-3-
carboxylate).
Alpha-ethyltryptamine.............. 7249 I
Ibogaine........................... 7260 I
CP-47,497 (5-(1,1-Dimethylheptyl)-2- 7297 I
[(1R,3S)-3-hydroxycyclohexyl-
phenol).
CP-47,497 C8 Homologue (5-(1,1- 7298 I
Dimethyloctyl)-2-[(1R,3S)3-
hydroxycyclohexyl-phenol).
Lysergic acid diethylamide......... 7315 I
2,5-Dimethoxy-4-(n)- 7348 I
propylthiophenethylamine (2C-T-7).
Marihuana.......................... 7360 I
Parahexyl.......................... 7374 I
Mescaline.......................... 7381 I
2-(4-Ethylthio-2,5-dimethoxyphenyl) 7385 I
ethanamine (2C-T-2 ).
3,4,5-Trimethoxyamphetamine........ 7390 I
4-Bromo-2,5-dimethoxyamphetamine... 7391 I
4-Bromo-2,5-dimethoxyphenethylamine 7392 I
4-Methyl-2,5-dimethoxyamphetamine.. 7395 I
2,5-Dimethoxyamphetamine........... 7396 I
JWH-398 (1-Pentyl-3-(4-chloro-1- 7398 I
naphthoyl) indole).
3,4-Methylenedioxyamphetamine...... 7400 I
5-Methoxy-3,4- 7401 I
methylenedioxyamphetamine.
N-Hydroxy-3,4- 7402 I
methylenedioxyamphetamine.
3,4-Methylenedioxy-N- 7404 I
ethylamphetamine.
3,4-Methylenedioxymethamphetamine.. 7405 I
4-Methoxyamphetamine............... 7411 I
[[Page 43406]]
5-Methoxy-N-N-dimethyltryptamine... 7431 I
Alpha-methyltryptamine............. 7432 I
Bufotenine......................... 7433 I
Diethyltryptamine.................. 7434 I
Dimethyltryptamine................. 7435 I
Psilocybin......................... 7437 I
Psilocyn........................... 7438 I
5-Methoxy-N,N-diisopropyltryptamine 7439 I
N-Ethyl-1-phenylcyclohexylamine.... 7455 I
1-(1-Phenylcyclohexyl)pyrrolidine.. 7458 I
1-[1-(2- 7470 I
Thienyl)cyclohexyl]piperidine.
N-Benzylpiperazine................. 7493 I
4-Methyl- 7498 I
alphapyrrolidinopropiophenone (4-
MePPP).
2-(2,5-Dimethoxy-4-methylphenyl) 7508 I
ethanamine (2C-D).
2-(2,5-Dimethoxy-4-ethylphenyl) 7509 I
ethanamine (2C-E ).
2-(2,5-Dimethoxyphenyl) ethanamine 7517 I
(2C-H).
2-(4-Iodo-2,5-dimethoxyphenyl) 7518 I
ethanamine (2C-I).
2-(4-Chloro-2,5-dimethoxyphenyl) 7519 I
ethanamine (2C-C).
2-(2,5-Dimethoxy-4-nitro-phenyl) 7521 I
ethanamine (2C-N).
2-(2,5-Dimethoxy-4-(n)- 7524 I
propylphenyl) ethanamine (2C-P).
2-(4-Isopropylthio)-2,5- 7532 I
dimethoxyphenyl) ethanamine (2C-T-
4 ).
MDPV (3,4- 7535 I
Methylenedioxypyrovalerone).
2-(4-bromo-2,5-dimethoxyphenyl)-N- 7536 I
(2-methoxybenzyl) ethanamine (25B-
NBOMe).
2-(4-chloro-2,5-dimethoxyphenyl)-N- 7537 I
(2-methoxybenzyl) ethanamine (25C-
NBOMe).
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- 7538 I
methoxybenzyl) ethanamine (25I-
NBOMe).
Methylone (3,4-Methylenedioxy-N- 7540 I
methylcathinone).
Butylone........................... 7541 I
Pentylone.......................... 7542 I
alpha-pyrrolidinopentiophenone 7545 I
([alpha]-PVP).
alpha-pyrrolidinobutiophenone 7546 I
([alpha]-PBP).
AM-694 (1-(5-Fluoropentyl)-3-(2- 7694 I
iodobenzoyl) indole).
Desomorphine....................... 9055 I
Etorphine (except HCl)............. 9056 I
Codeine methylbromide.............. 9070 I
Heroin............................. 9200 I
Morphine-N-oxide................... 9307 I
Normorphine........................ 9313 I
Pholcodine......................... 9314 I
U-47700 (3,4-dichloro-N-[2- 9547 I
dimethylamino)cyclohexy]-N-
methylbenzamide).
AH-7921 (3,4-dichloro-N-[(1- 9551 I
dimethylamino)cyclohexylmethyl]ben
zamide)).
Acetylmethadol..................... 9601 I
Allylprodine....................... 9602 I
Alphacetylmethadol except levo- 9603 I
alphacetylmethadol.
Alphameprodine..................... 9604 I
Alphamethadol...................... 9605 I
Betacetylmethadol.................. 9607 I
Betameprodine...................... 9608 I
Betamethadol....................... 9609 I
Betaprodine........................ 9611 I
Dextromoramide..................... 9613 I
Dipipanone......................... 9622 I
Hydroxypethidine................... 9627 I
Noracymethadol..................... 9633 I
Norlevorphanol..................... 9634 I
Normethadone....................... 9635 I
Racemoramide....................... 9645 I
Trimeperidine...................... 9646 I
1-Methyl-4-phenyl-4- 9661 I
propionoxypiperidine.
Tilidine........................... 9750 I
Para-Fluorofentanyl................ 9812 I
3-Methylfentanyl................... 9813 I
Alpha-methylfentanyl............... 9814 I
Acetyl-alpha-methylfentanyl........ 9815 I
Beta-hydroxyfentanyl............... 9830 I
Beta-hydroxy-3-methylfentanyl...... 9831 I
Alpha-methylthiofentanyl........... 9832 I
3-Methylthiofentanyl............... 9833 I
Thiofentanyl....................... 9835 I
Methamphetamine.................... 1105 II
Methylphenidate.................... 1724 II
Amobarbital........................ 2125 II
Pentobarbital...................... 2270 II
Secobarbital....................... 2315 II
Glutethimide....................... 2550 II
[[Page 43407]]
Nabilone........................... 7379 II
1-Phenylcyclohexylamine............ 7460 II
Phencyclidine...................... 7471 II
Phenylacetone...................... 8501 II
1-Piperidinocyclohexanecarbonitrile 8603 II
Alphaprodine....................... 9010 II
Dihydrocodeine..................... 9120 II
Ecgonine........................... 9180 II
Ethylmorphine...................... 9190 II
Levomethorphan..................... 9210 II
Levorphanol........................ 9220 II
Meperidine......................... 9230 II
Dextropropoxyphene, bulk (non- 9273 II
dosage forms).
Levo-alphacetylmethadol............ 9648 II
Noroxymorphone..................... 9668 II
Racemethorphan..................... 9732 II
Alfentanil......................... 9737 II
Remifentanil....................... 9739 II
Sufentanil......................... 9740 II
Carfentanil........................ 9743 II
Tapentadol......................... 9780 II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the manufacture of analytical reference
standards and distribution to their research and forensic customers.
In reference to drug code 7360 the company plans to import a
synthetic cannabidiol. No other activity for this drug code is
authorized for this registration.
Placement of these drug codes onto the company's registration does
not translate into automatic approval of subsequent permit applications
to import controlled substances. Approval of permit applications will
occur only when the registrant's business activity is consistent with
what is authorized under 21 U.S.C. 952(a)(2). Authorization will not
extend to the import of FDA approval or non-approved finished dosage
forms for commercial sale.
Dated: August 31, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-19067 Filed 9-14-17; 8:45 am]
BILLING CODE 4410-09-P
